Category: Safety Assessment

Experimental Pathology Laboratories, Inc. Welcomes Dr. Elizabeth Galbreath!

Elizabeth J. Galbreath, DVM, PhD, DACVP – Senior Pathologist, Manager EPL-Boston, MA Dr. Elizabeth Galbreath joins Experimental Pathology Laboratories, Inc. (EPL) as a Senior Pathologist and Manager of EPL-Boston, MA.  In addition, Dr. Galbreath will be available as a Principal Consultant for Aclairo Pharmaceutical Development Group Inc, an EPL company. Dr. Galbreath will be available […]

PathologySafety AssessmentToxicology

Experimental Pathology Laboratories, Inc. Welcomes Dr. Jim Fikes!

James (Jim) D. Fikes, DVM, PhD, DACVP, DABVT – Senior Pathologist, Manager EPL-Boston, MA Dr. Jim Fikes joins Experimental Pathology Laboratories, Inc. (EPL) as a Senior Pathologist and Manager of EPL-Boston, MA.  Dr. Fikes will be responsible for the pathology phases of commercial client’s various toxicology studies to include consultation services, initial histopathology evaluation, pathology […]

PathologySafety AssessmentToxicology

Blind Slide Reading

In toxicologic pathology, “blind slide reading” involves procedures in which the pathologist is unaware of the treatment group status of individual animals during the histologic slide evaluation phase of a toxicologic bioassay.  Blind slide reading continues to be a controversial topic, despite published recommendations on this subject authored by professional societies and governmental regulatory agencies […]

PathologySafety AssessmentToxicology

Immunostaining Assay Optimization – Tackling Intrinsic Study Variables

Immunohistochemistry or Immunofluorescence (IHC/IF) is employed routinely for investigative and diagnostic evaluations of antigen-antibody interactions within cells or tissues. While most IHC/IF target antigens are proteins, other antigenic biological substrates can also be recognized by antibodies (e.g., carbohydrates, lipids, or nucleic acids). Accurate and reproducible results are achieved when procedures used to identify and localize […]

DiscoveryHistologyPathologySafety AssessmentToxicology

EPL – Independent and Employee-Owned

Experimental Pathology Laboratories, Inc. (EPL) is an independent, private, employee-owned company that is recognized internationally for its ability to meet the needs of the scientific community and the challenges of preclinical safety testing and development with high quality histopathology services.  EPL was founded in 1971, and became an employee-owned company in 1992.  EPL is proud […]

DiscoveryHistologyPathologySafety AssessmentToxicology

Aclairo Welcomes Dr. Heath Thomas as New President

Experimental Pathology Laboratories, Inc. (EPL) and Aclairo Pharmaceutical Development Group, Inc. (Aclairo) are excited to announce that Dr. Heath Thomas has joined Aclairo as President and Senior Consultant. Dr. Thomas is a board-certified veterinary pathologist with over 20 years of experience in drug development from time spent with SmithKline Beecham, DuPont Pharmaceuticals, and GlaxoSmithKline, as […]

Biological TestingClinical Pharmacology & ModelingDiscoveryPathologySafety AssessmentToxicology

Navigating the FDA Guidance for Nonclinical Abuse Liability Testing

The goal of this discussion is to help one understand and address the Food and Drug Administration’s Guidance for Industry, “Assessment of Abuse Potential of Drugs” Drug abuse is the intentional, non-therapeutic use of a drug or substance to achieve a desired psychological or physiological effect.  Abuse potential is a characteristic of a drug that […]

Safety Assessment

Using Transmission Electron Microscopy in Preclinical Safety Studies

The use of Transmission Electron Microscopy (TEM) in preclinical studies has significantly waned in the last 20 or so years.  There are multiple reasons for this.  TEM is expensive and labor intensive.  Compared to standard histopathology, TEM requires significantly more time and money to analyze samples.  The cost of maintaining an electron microscope is practical […]

HistologyPathologySafety AssessmentToxicology

On-Time Pathology Reporting

It is every client’s desire and expectation that their study report will be completed “On-Time” or better yet, be available ahead of schedule. There are a number of factors that determine whether a pathology report will be early, on time, or in the worst case scenario, delayed. Most situations are readily managed, but in rare […]

HistologyPathologySafety AssessmentToxicology

EXPEDITED SCHEDULING OF HISTOLOGY AND HISTOPATHOLOGY

Kerry Crabb, HTL(ASCP), is the Manager of North Carolina Laboratory Operations at EPL. Kerry joined EPL in 2015, and brought with him over 25 years of experience in managing histology laboratories. Kerry’s experience at both large pharmaceutical and agrochemical companies gave him a broad knowledge on some of the best practices related to histology and […]

HistologyPathologySafety AssessmentToxicology